OCULAR THERAPEUTIX INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards, including stock options and restricted stock units, or RSUs, and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other of our securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Pravin U. Dugel(President and Chief Executive Officer, Executive Chairman) | Adoption (February 21, 2024) | Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted | Sale | Until final settlement of any covered RSUs | Indeterminable (1) |
| Antony Mattessich (President and Chief Executive Officer until April 14, 2024) | Adoption (March 14, 2024) | Rule 10b5-1 trading arrangement for sale of vested stock options | Sale | September 15, 2026, or such earlier date upon which all transactions are completed or expire without execution | Up to 969,370 |
|---|---|---|---|---|---|
| Sanjay Nayak (Chief Strategy Officer) | Adoption (February 21, 2024) | Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted | Sale | Until final settlement of any covered RSUs | Indeterminable (1) |
| Donald Notman (Chief Financial Officer) | Adoption (March 15, 2024) | Rule 10b5-1 trading arrangement for sale of vested stock options | Sale | March 15, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 125,000 |
| Philip C. Strassburger (General Counsel) | Adoption (March 14, 2024) | Rule 10b5-1 trading arrangement for sale of vested stock options and shares of common stock | Sale | December 31, 2024, or such earlier date upon which all transactions are completed or expire without execution | Up to 69,118 |
(1) The number of shares subject to covered RSUs that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement. This trading arrangement, which applies to RSUs whether vesting is based on the passage of time and/or the achievement of performance goals, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a covered RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.